COVID-19 and Cardiovascular Disease

Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.

Keywords: COVID-19; cardiovascular diseases; pandemics; severe acute respiratory syndrome coronavirus 2.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Cardiovascular Diseases* / complications
  • Cardiovascular Diseases* / enzymology
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / drug therapy
  • Coronavirus Infections* / enzymology
  • Coronavirus Infections* / therapy
  • Coronavirus Infections* / virology
  • Humans
  • Pandemics*
  • Peptidyl-Dipeptidase A* / metabolism
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / enzymology
  • Pneumonia, Viral* / therapy
  • Pneumonia, Viral* / virology
  • Receptors, Virus / antagonists & inhibitors
  • Receptors, Virus / metabolism
  • SARS-CoV-2

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Receptors, Virus
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2

Supplementary concepts

  • COVID-19 drug treatment